Assessment of tumourigenic potential in long‐term cryopreserved human adipose‐derived stem cells. (12th January 2016)

• Record Type: Journal Article
• Authors: Yong, Kar Wey; Safwani, Wan Kamarul Zaman Wan; Xu, Feng; Zhang, Xiaohui; Choi, Jane Ru; Abas, Wan Abu Bakar Wan; Omar, Siti Zawiah; Azmi, Mat Adenan Noor; Chua, Kien Hui; Pingguan‐Murphy, Belinda
• Is Part Of: Journal of tissue engineering and regenerative medicine. Volume 11:Number 8(2017)
• Page Start: 2217
• Page End: 2226
• Publication Date: 2016-01-12
• Subjects: long‐term cryopreservation -- human adipose‐derived stem cells -- tumourigenic potential assessment -- low risk -- biosafety -- clinical applications; Tissue engineering -- Periodicals; Regeneration (Biology) -- Periodicals; 610.28
• DOI: 10.1002/term.2120
• Languages: English
• ISSNs: 1932-6254

Abstract

Abstract: Cryopreservation represents an efficient way to preserve human mesenchymal stem cells (hMSCs) at early culture/passage, and allows pooling of cells to achieve sufficient cells required for off‐the‐shelf use in clinical applications, e.g. cell‐based therapies and regenerative medicine. To fully apply cryopreserved hMSCs in a clinical setting, it is necessary to evaluate their biosafety, e.g. chromosomal abnormality and tumourigenic potential. To date, many studies have demonstrated that cryopreserved hMSCs display no chromosomal abnormalities. However, the tumourigenic potential of cryopreserved hMSCs has not yet been evaluated. In the present study, we cryopreserved human adipose‐derived mesenchymal stem cells (hASCs) for 3 months, using a slow freezing method with various cryoprotective agents (CPAs), followed by assessment of the tumourigenic potential of the cryopreserved hASCs after thawing and subculture. We found that long‐term cryopreserved hASCs maintained normal levels of the tumour suppressor markers p53, p21, p16 and pRb, hTERT, telomerase activity and telomere length. Further, we did not observe significant DNA damage or signs of p53 mutation in cryopreserved hASCs. Our findings suggest that long‐term cryopreserved hASCs are at low risk of tumourigenesis. These findings aid in establishing the biosafety profile of cryopreserved hASCs, and thus establishing low hazardous risk perception with the use of long‐term cryopreserved hASCs for future clinical applications. Copyright © 2016 John Wiley & Sons, Ltd.